GeneDx Holdings Corp. (WGS) is a publicly traded company in the Unknown sector. Across all available filings, 21 corporate insiders have executed 307 transactions totaling $166.9M, demonstrating a bearish sentiment with -$59.3M in net insider flow. The most recent transaction on Dec 16, 2025 involved a sale of 274 shares valued at $40.9K.
No significant insider buying has been recorded for WGS in the recent period.
No significant insider selling has been recorded for WGS in the recent period.
Based on recent SEC filings, insider sentiment for WGS is bearish with an Insider Alignment Score of 32/100 and a net flow of -$59.3M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at GeneDx Holdings Corp. (WGS) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 21 insiders are actively trading WGS stock, having executed 307 transactions in the past 90 days. The most active insider is Eli Casdin (Executive), who has made 10 transactions totaling $94.7M.
Get notified when executives and directors at WGS file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Dec 16, 2025 | Stueland Katherine | Executive | Sale | 274 | $149.20 | $40.9K | |
| Dec 16, 2025 | Stueland Katherine | Executive | Sale | 1,970 | $146.93 | $289.5K | |
| Dec 16, 2025 | Stueland Katherine | Executive | Sale | 1,628 | $145.36 | $236.6K | |
| Dec 16, 2025 | Stueland Katherine | Executive | Sale | 940 | $144.27 | $135.6K | |
| Dec 16, 2025 | Stueland Katherine | Executive | Sale | 74 | $150.75 | $11.2K | |
| Dec 16, 2025 | Stueland Katherine | Executive | Sale | 356 | $140.95 | $50.2K | |
| Dec 16, 2025 | Stueland Katherine | Executive | Option Exercise | 18,750 | $N/A | $0 | |
| Dec 16, 2025 | Stueland Katherine | Executive | Sale | 369 | $138.93 | $51.3K | |
| Dec 16, 2025 | Stueland Katherine | Executive | Sale | 1,031 | $140.08 | $144.4K | |
| Dec 16, 2025 | Stueland Katherine | Executive | Sale | 2,679 | $141.20 | $378.3K | |
| Dec 16, 2025 | Stueland Katherine | Executive | Sale | 604 | $142.12 | $85.8K | |
| Dec 16, 2025 | Stueland Katherine | Executive | Sale | 932 | $148.55 | $138.4K | |
| Dec 16, 2025 | Feeley Kevin | Executive | Sale | 97 | $149.20 | $14.5K | |
| Dec 16, 2025 | Feeley Kevin | Executive | Sale | 26 | $150.75 | $3.9K | |
| Dec 16, 2025 | Feeley Kevin | Executive | Sale | 127 | $140.45 | $17.8K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 175 | $113.1M | 52.2% |
Purchase(P) | 18 | $53.8M | 24.8% |
Award(A) | 6 | $36.5M | 16.8% |
Other(J) | 1 | $13.3M | 6.2% |
Exercise(M) | 106 | $81.4K | 0.0% |
Gift(G) | 1 | $0 | 0.0% |
Insider selling pressure at GeneDx Holdings Corp. has increased, with 21 insiders executing 307 transactions across all time. Total sales of $113.1M significantly outpace purchases of $53.8M, resulting in a net outflow of $59.3M. This selling activity appears largely discretionary, which may warrant closer attention from investors.